-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Benzinga·09/09/2026 14:59:34
Listen to the news
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.